

"A.M.A. Aide Let Upjohn Use Letter To Sell Drug," by David Burnham, article from The New York Times, July 8, 1975.....	13413
"Oral Hypoglycemic Agents," excerpt from the Pharmacological Basis of Therapeutics, fifth edition, Goodman and Gilman, pages 1519-1524.....	13414
Letter dated August 21, 1975, to hearing clerk, Food and Drug Administration, from Max Miller, M.D., professor, Case Western Reserve University.....	13421
Presentation of Sidney M. Wolfe, M.D., and Anita Johnson, Public Citizen's Health Research Group, to the FDA hearings on proposed labeling for diabetes drugs, August 20, 1975.....	13423
"Oral Hypoglycemic Agents Are Worthwhile," by Robert F. Bradley, M.D., Joslin Clinic, Boston, Mass.	13427
"AMA Official Let Company Use Name," by Stuart Auerbach, article from the Washington Post, July 9, 1975.....	13439
Letter dated February 17, 1975, to Senator Gaylord Nelson, Chairman, Select Committee on Small Business, U.S. Senate, from Dr. Paul Meier, Professor of Statistics, University of Chicago.....	13440
Letter dated March 11, 1975, to Senator Gaylord Nelson, Chairman, Select Committee on Small Business, U.S. Senate, from Herbert H. McDade, Jr., President and Chief Operating Officer, USV Pharmaceutical Corp.....	13448
Letter dated April 1, 1975, to Hon. Alexander M. Schmidt, M.D., Commissioner, Food and Drug Administration, from Senator Gaylord Nelson, Chairman, Select Committee on Small Business, U.S. Senate.....	13452
Letter dated April 10, 1975, to Senator Gaylord Nelson, Chairman, Select Committee on Small Business, U.S. Senate, from Robert C. Wetherell, Jr., Director, Office of Legislative Services, Food and Drug Administration.....	13453
Letter dated February 14, 1975, to Senator Gaylord Nelson, Chairman, Select Committee on Small Business, U.S. Senate, from Neil L. Chayet, Attorney at Law, Chayet and Sonnenreich, P. C., with accompanying enclosure.....	13454
Letter dated May 27, 1975, to Neil L. Chayet, Attorney at Law, Chayet and Sonnenreich, P. C., from Benjamin Gordon, Staff Economist, Select Committee on Small Business, U.S. Senate.....	13457
Letter dated July 10, 1975, to Benjamin Gordon, Staff Economist, Select Committee on Small Business, U.S. Senate, from Neil L. Chayet, Attorney at Law, Chayet and Sonnenreich, P. C., with accompanying enclosure.....	13457
Notice of Public Hearing and Proposed Labeling by the Food and Drug Administration, Department of Health, Education, and Welfare, 21 CFR Part 310, Docket No. 75N-0062, July 1, 1975.....	13462
Letter dated June 10, 1975, to Alexander M. Schmidt, M.D., Commissioner, Food and Drug Administration, from Sidney M. Wolfe, M.D., Health Research Group.....	13530
"The FDA and Hypoglycemic Drugs," by John K. Davidson, M.D., Ph.D., article from the Journal of the American Medical Association, Vol. 232, No. 8, May 26, 1975, pages 853-855.....	13535
"Government Rx's—FDA Proposes Important Revision," article from Drug Therapy, January 1975.....	13538
"Oral Antidiabetic Agents Have a Limited Place in Management and May Be Harmful," by Albert I. Winegrad, Rex S. Clements, Jr., and Anthony D. Morrison, University of Pennsylvania School of Medicine.....	13541
"In Vitro Effects of Tolbutamide on the Sympatho-Adrenal System," by Chung-Yi Hsu, Gary Brooker, Michael J. Peach, Thomas C. Westfall, and Joseph Larner, article from Diabetes, Vol. 24, Supplement 2, June 15, 1975.....	13556
"A Study of the Chronic Effects of Tolbutamide in the Rhesus Monkey," by J. Borensztajn, G. S. Getz, S. Glagov, A. Rubenstein, C. H. Ts'ao, and R. W. Wissler, FDA No. 72-114, February 15, 1975.....	13560
Letter dated May 30, 1975, to Senator Gaylord Nelson, Chairman, Select Committee on Small Business, U.S. Senate, from Robert C. Wetherell, Jr., Director, Office of Legislative Services, Food and Drug Administration, with accompanying enclosures.....	13568